Eli Lilly (LLYD) Hisse Özeti

Eli Lilly and Company, Amerika Birleşik Devletleri, Avrupa, Çin, Japonya ve uluslararası alanda beşeri ilaçları keşfetmekte, geliştirmekte ve pazarlamaktadır. Daha fazla detay

LLYD temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	5/6
Finansal Sağlık	5/6
Temettüler	4/6

Ödüller

Adil değer tahminimizden 9.4% daha düşük bir oranda işlem görüyor

Kazançların yılda 16.22% oranında artması öngörülüyor

Kazançlar geçen yıl 93.6% oranında arttı

Risk Analizi

Yüksek borç seviyesine sahip

Last Earnings Call

Q2 2026 · 5 Aug 2026

Full Transcript

Eli Lilly reported strong Q2 2026 financial results on August 5, 2026, driven by robust volume growth in its incretin portfolio.

Financial Results & Metrics

Revenue: Reported $23.0 billion, a 48% increase year-over-year, beating analyst consensus of approximately $20.69 billion.
EPS: Non-GAAP EPS was $8.38, which beat consensus estimates (varying reports cited $6.01–$6.06 as the consensus expectation, though some sources noted a $8.84 target). Reported EPS was $7.94.
Key Products: Mounjaro and Zepbound continued to drive growth, with Mounjaro revenue reaching approximately $9.94 billion.
Management Outlook: Lilly raised its full-year 2026 revenue guidance to a range of $85.0 billion–$87.0 billion (up from $82.0 billion–$85.0 billion) and set full-year non-GAAP EPS guidance at $35.50–$36.50.

Market Reaction

Eli Lilly stock rose approximately 6.3% on August 5, 2026. Analysts attributed the positive market response to the company's strong revenue beat, upward guidance revision, and successful scaling of manufacturing capacity, which reassured investors regarding the supply of its high-demand metabolic therapies.

LLYD Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW474,777 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

474,777 investors already sharing narratives

View all narratives

Eli Lilly and Company Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Eli Lilly
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$21.96
52 Haftanın En Yüksek Seviyesi	US$23.19
52 Haftanın En Düşük Seviyesi	US$11.20
Beta	0.51
1 Aylık Değişim	-1.96%
3 Aylık Değişim	25.49%
1 Yıllık Değişim	94.34%
3 Yıllık Değişim	125.73%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	290.15%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	LLYD	AR Pharmaceuticals	AR Pazar
7D	3.0%	0.2%	-4.5%
1Y	94.3%	28.8%	27.7%

Getiri vs. Endüstri: LLYD geçen yıl % 28.8 oranında getiri sağlayan AR Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: LLYD geçen yıl % 27.7 oranında getiri sağlayan AR Piyasasını aştı.

Fiyat Oynaklığı

Is LLYD's price volatile compared to industry and market?
LLYD volatility
LLYD Average Weekly Movement	4.7%
Pharmaceuticals Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in AR Market	7.1%
10% least volatile stocks in AR Market	3.0%

İstikrarlı Hisse Senedi Fiyatı: LLYD son 3 ayda AR piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: LLYD 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1876	50,000	Dave Ricks	www.lilly.com

Eli Lilly and Company, Amerika Birleşik Devletleri, Avrupa, Çin, Japonya ve uluslararası alanda beşeri ilaçları keşfetmekte, geliştirmekte ve pazarlamaktadır. Şirket diyabet için Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R ve Humulin U-500; tip 2 diyabet için Jardiance, Mounjaro ve Trulicity; ve obezite için Zepbound ürünlerini sunmaktadır. Ayrıca Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt ve Verzenio dahil olmak üzere onkoloji ürünleri de sunmaktadır.

Eli Lilly and Company Temel Bilgiler Özeti

Eli Lilly'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
LLYD temel i̇stati̇sti̇kler
Piyasa değeri	US$1.06t
Kazançlar(TTM)	US$26.71b
Gelir(TTM)	US$79.67b

39.6x

F/K Oranı

13.3x

P/S Oranı

LLYD aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
LLYD gelir tablosu (TTM)
Gelir	US$79.67b
Gelir Maliyeti	US$13.23b
Brüt Kâr	US$66.44b
Diğer Giderler	US$39.73b
Kazançlar	US$26.71b

Son Raporlanan Kazançlar

Jun 30, 2026

Sonraki Kazanç Tarihi

Oct 29, 2026

Hisse başına kazanç (EPS)	29.97
Brüt Marj	83.40%
Net Kâr Marjı	33.53%
Borç/Özkaynak Oranı	162.1%

LLYD uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

0.6%

Mevcut Temettü Verimi

22%

Ödeme Oranı

LLYD güvenilir bir temettü ödüyor mu?

LLYD temettü geçmişine ve kıyaslamalara bakın

Yaklaşan bir temettüyü almak için ne zaman LLYD satın almanız gerekir?
Eli Lilly temettü tari̇hleri̇
Eski Temettü Tarihi	Aug 14 2026
Temettü Ödeme Tarihi	Sep 10 2026
Eski temettüye kadar geçen günler	6 days
Temettü ödeme tarihine kadar geçen günler	33 days

LLYD güvenilir bir temettü ödüyor mu?

LLYD temettü geçmişine ve kıyaslamalara bakın

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/08/07 21:47
Gün Sonu Hisse Fiyatı	2026/08/07 00:00
Kazançlar	2026/06/30
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Eli Lilly and Company 52 Bu analistlerden 24, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
David Toung	Argus Research Company
Emily Field	Barclays
Kerry Holford	Berenberg

Eli Lilly (LLYD) Hisse Özeti

Ödüller

Risk Analizi

Financial Results & Metrics

Market Reaction

Join community and earn perks

Eli Lilly and Company Rakipler

Johnson & Johnson

Novartis

Roche Holding

Merck

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Eli Lilly and Company Updates Earning Guidance for the Year 2026

Eli Lilly and Company Receives Fda Breakthrough Therapy Designation for Olomorasib as Monotherapy for Previously Treated Kras G12c-Mutant Advanced Pancreatic Cancer

Eli Lilly and Company (NYSE:LLY) entered into an Agreement and Plan of Merger to acquire AtaiBeckley Inc. (NasdaqGM:ATAI) from Apeiron Investment Group Limited and others for $2.6 billion.

Eli Lilly And Company Receives Positive Opinion From CHMP For Jaypirca For Treatment Of Adults With Chronic Lymphocytic Leukemia Across All Lines Of Therapy

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Centessa Pharmaceuticals plc (NasdaqGS:CNTA) from Medicxi Ventures (UK) LLP, Index Ventures SA, General Atlantic Service Company, L.P. and other shareholders.

Eli Lilly and Company Declares Dividend for the Third Quarter of 2026, Payable on September 10, 2026

Recent updates

Eli Lilly and Company Updates Earning Guidance for the Year 2026

Eli Lilly and Company Receives Fda Breakthrough Therapy Designation for Olomorasib as Monotherapy for Previously Treated Kras G12c-Mutant Advanced Pancreatic Cancer

Eli Lilly and Company (NYSE:LLY) entered into an Agreement and Plan of Merger to acquire AtaiBeckley Inc. (NasdaqGM:ATAI) from Apeiron Investment Group Limited and others for $2.6 billion.

Eli Lilly And Company Receives Positive Opinion From CHMP For Jaypirca For Treatment Of Adults With Chronic Lymphocytic Leukemia Across All Lines Of Therapy

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Centessa Pharmaceuticals plc (NasdaqGS:CNTA) from Medicxi Ventures (UK) LLP, Index Ventures SA, General Atlantic Service Company, L.P. and other shareholders.

Eli Lilly and Company Declares Dividend for the Third Quarter of 2026, Payable on September 10, 2026

Eli Lilly and Company (NYSE:LLY) acquired 4E Therapeutics Inc.

Eli Lilly and Company Receives Fda Approval for EBGLYSS Maintenance Dose Every Eight Weeks in Patients with Moderate-To-Severe Atopic Dermatitis

Eli Lilly And Company Delivers Superior A1C Control And Weight Loss With Foundayo In Three Pivotal Type 2 Diabetes Trials

Eli Lilly And Company Announces Results From Phase 3 LIBRETTO-432 Clinical Trial Of Retevmo (Selpercatinib) As Adjuvant Therapy Versus Placebo In Patients With Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer

Eli Lilly and Company Presents New Data on Foundayo, Mounjaro and Retatrutide At the American Diabetes Association's 86Th Scientific Sessions

Eli Lilly and Company Announces Expanded Coverage for Foundayo and Zepbound Obesity Medicines

Eli Lilly and Company (NYSE:LLY) entered into an agreement to acquire Curevo, Inc. from HBM Healthcare Investments AG (SWX:HBMN), a fund managed by HBM Partners Ltd., and others for $1.5 billion.

Eli Lilly and Company Showcases Oncology Portfolio Across Tumor Types and Treatment Modalities At the American Society of Clinical Oncology Annual Meeting

Eli Lilly and Company Announces Results of Retatrutide Phase 3 Clinical Trial

Walden Macht Haran & Williams LLP Secures Victory Against Eli Lilly and Company

Eli Lilly and Company Presents Results for Foundayo and Zepbound in Weight Loss Maintenance Trials

Eli Lilly and Company Announces Omvoh Demonstrates Durable Disease Clearance in Ulcerative Colitis Through Four Years

Eli Lilly and Company Raises Earning Guidance for the Year 2026

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire remaining majority stake in Ajax Therapeutics, Inc. for $2.3 billion.

Lilly Reportedly in Advanced Talks to Acquire Kelonia Therapeutics for over $2 Billion

Eli Lilly and Company Announces Positive Topline Results from Phase 3 Achieve-4 Trial Evaluating Foundayo (Orforglipron) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight At Increased Cardiovascular Risk

Eli Lilly And Company Announces Positive Phase 3 Results For Jaypirca (Pirtobrutinib) In Previously Treated CLL/SLL

Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S

Eli Lilly And Company Receives FDA Approval For Foundayo (Orforglipron) For Weight Loss

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Centessa Pharmaceuticals plc (NasdaqGS:CNTA) from Medicxi Ventures (UK) LLP, Index Ventures SA, General Atlantic Service Company, L.P. and other shareholders for $5.6 billion.

Eli Lilly and Company Presents Phase 3B Data on Taltz and Zepbound Combination for Adults with Psoriatic Arthritis and Obesity

Eli Lilly And Company Delivers Durable Disease Control With Ebglyss For Moderate-To-Severe Atopic Dermatitis

Eli Lilly And Company Demonstrates Significant Reductions In A1C And Weight With Retatrutide In First Phase 3 Trial For Treatment Of Type 2 Diabetes

Eli Lilly And Company Announces Positive Phase 3 Results For EBGLYSS In Pediatric Patients With Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Company, Annual General Meeting, May 04, 2026

Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company Announce National Third-Party Payor Class Certified in Lawsuit Regarding Actos

Eli Lilly and Company Launches Employer Connect Platform with Tailored Obesity Coverage Options

Eli Lilly and Company's Olumiant Recommends by CHMP for Approval of Expanded Use in the European Union for Adolescents with Severe Alopecia Areata

Eli Lilly and Company Announces Detailed Results from ACHIEVE-3

Eli Lilly and Company Announces the U.S. Food and Drug Administration Approves a Label Expansion for Zepbound® (tirzepatide)

Eli Lilly and Company Presents New Long-Term Data from Eli Lilly and Company's Omvoh (mirikizumab-mrkz)

Eli Lilly and Company Announces Positive Topline Results from Taltz (Ixekizumab) and Zepbound (Tirzepatide)

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 LIBRETTO-432 Clinical Trial of Retevmo

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Orna Therapeutics, Inc. in a transaction valued at $2.4 billion.

Eli Lilly and Company Provides Earnings Guidance for the Full Year 2026

Eli Lilly and Company to Report Q4, 2025 Results on Feb 04, 2026

Eli Lilly and Company's Sofetabart Mipitecan Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Patients with Platinum-Resistant Ovarian Cancer

Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk

Eli Lilly and Company Announces Positive Topline Results from the Novel TOGETHER-PsA Open-Label Phase 3b Trial Evaluating the Concomitant Use of Taltz (Tirzepatide)

Eli Lilly and Company (NYSE:LLY) entered into an Agreement and Plan of Merger to acquire Ventyx Biosciences, Inc. (NasdaqGS:VTYX) from New Science Ventures, LLC and others for approximately $1 billion.

Ventyx Biosciences Reportedly in $1 Billion Acquisition Talks with Eli Lilly

Celltrion, Inc. (KOSE:A068270) acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).

Eli Lilly and Company Announces Oral GLP-1 Orforglipron

Eli Lilly and Company Announces Positive Topline Results from the ATTAIN-MAINTAIN trial

Eli Lilly and Company Announces Updated Data for Lilly's Inluriyo™ (Imlunestrant) Reinforce Efficacy Results as Monotherapy and in Combination with Verzenio® (Abemaciclib) in Er+, Her2- Advanced Breast Cancer

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 TRIUMPH-4 Clinical Trial

Eli Lilly and Company Announces Results from the Phase 3 Bruin CLL-313 Clinical Trial of Jaypirca (Pirtobrutinib)

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Expanded Indication for Lilly's Jaypirca (Pirtobrutinib, 100 Mg & 50 Mg Tablets)

Wisner Baum Unleashes Rico Against Takeda Pharmaceuticals and Eli Lilly

Eli Lilly and Company to Present Data from Two Positive Phase 3 Studies of Jaypirca (Pirtobrutinib) in Chronic Lymphocytic Leukemia at the 2025 American Society of Hematology Annual Meeting

Eli Lilly and Company Announces Appointment of Carolyn R. Bertozzi, Ph.D as New Board Member and Member of Science and Technology Committee and the Ethics and Compliance Committee, Effective December 8, 2025

Eli Lilly and Company Announces Management Appointments

Eli Lilly and Company Announces Positive Results from A Phase 2 Trial Evaluating the Safety and Efficacy of Eloralintide

Eli Lilly and Company Raises Earnings Guidance for the Year 2025